The pharmaceutical industry faces a transformative shift as drug pricing pressures intensify in the US market, with the September 29 deadline approaching for companies to implement Most Favored Nation pricing. Marketing strategies must evolve from traditional branding to outcomes-based approaches that demonstrate real value as margins tighten and price becomes a non-negotiable factor.
• Marketing budgets shifting toward outcome-based strategies that demonstrate improved adherence and access
• Real-world evidence emerging as critical currency to justify medication value beyond scientific efficacy
• Brand differentiation increasingly dependent on patient experience rather than price points
• Product lifecycle marketing accelerating to establish strong launch momentum before price erosion
• Growing investment in adherence programs to maximize value from each prescription
• Patient-centric pricing narratives focusing on equity, access and affordability becoming essential
• Multi-channel personalization delivering 54% higher engagement metrics through targeted communications
If you found this conversation valuable, follow or subscribe for more insights as we keep an eye on the intersection of pharma tech and patient impact. The real work begins after the script is written.
PostScripts Rx is not intended to constitute medical advice, nor is it intended to influence prescribing decisions or any other medical or clinical decision-making. All medical and clinical judgment and decision-making, prescribing decisions, and all related considerations remain exclusively the responsibility of providers and patients.
